[Federal Register: December 1, 2003 (Volume 68, Number 230)]
[Notices]
[Page 67177-67181]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr01de03-78]
[[Page 67177]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Rapid Strengthening of Blood Transfusion Services in Selected
Countries in Africa and the Caribbean for the Ministries of Health and
National Transfusion Services Under the President's Emergency Plan for
AIDS Relief
Announcement Type: New, Cooperative Agreement.
Funding Opportunity Number: 04077.
Catalog of Federal Domestic Assistance Number: 93.943.
Key Dates:
[sbull] Application Deadline: March 1, 2004.
Executive Summary: An important aspect of the President Bush's
Emergency Plan for AIDS Relief is to provide assistance to ensure a
safe and adequate blood supply. The focus of this initiative is 14
countries in Africa and the Caribbean heavily affected by HIV/AIDS:
Botswana, C[ocirc]te d'Ivoire, Ethiopia, Haiti, Guyana, Kenya,
Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania, Uganda,
and Zambia. The purpose of this announcement is to rapidly provide
support to the Ministries of Health or the Government's National
Transfusion Services in the 14 targeted countries, with the goal of
developing and implementing a national safe blood program with
demonstrable results within the first year of the Emergency Plan.
Specific activities include implementation of blood safety programs,
including management, operations, and monitoring.
I. Funding Opportunity Description
Authority: This program is authorized under section 301(a) and
307 of the Public Health Service Act, [42 U.S.C. 241 (a) and 242l]
as amended and under Public Law 108-25 (United States Leadership
Against HIV/AIDS, Tuberculosis and Malaria Act of 2003) [22 U.S.C.
7601].
Purpose: President Bush's Emergency Plan for AIDS Relief has called
for immediate action to turn the tide of HIV/AIDS in Africa and the
Caribbean, preventing at least seven million HIV infections within five
years. An important aspect of the President's plan is to provide
assistance to ensure a safe and adequate blood supply. The focus of
this initiative is 14 countries in Africa and the Caribbean heavily
affected by HIV/AIDS: Botswana, C[ocirc]te d'Ivoire, Ethiopia, Haiti,
Guyana, Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa,
Tanzania, Uganda, and Zambia. The World Health Organization (WHO)
estimates that five to ten percent of all HIV transmissions are
attributable to unsafe blood transfusions. Transmission of HIV and
other blood-borne pathogens via blood transfusion is preventable by
establishing an adequate supply of safe blood through a systematized
blood transfusion service and minimizing unnecessary transfusions.
However, according to the WHO, among blood donations in Africa in 2002,
only 90 percent were screened for HIV, 55 percent for Hepatitis B
virus, and only 40 percent for Hepatitis C virus.
The rapid implementation of safe blood programs and precautions
against medical transmission of HIV is a priority area for the
President's plan. The purpose of this announcement is to rapidly
provide support to Ministries of Health and National Transfusion
Services in the 14 targeted countries, with the goal of developing and
implementing a national safe blood program in each country with
demonstrable results even within the first year of the Emergency Plan.
Measurable outcomes of this program will be in alignment with the
following performance goal for President Bush's Emergency Plan for AIDS
Relief: Prevent 7 million new HIV infections. The initiative will
involve large-scale prevention efforts, including the rapid
establishment and strengthening of safe blood transfusion services.
This initiative is a coordinated effort led by the Office of the
Global AIDS Coordinator at the Department of State and involves various
U.S. Federal Government agencies, including, the Department of State,
the Department of Health and Human Services (HHS), the Department of
Defense, and the U.S. Agency for International Development.
Activities: Awardee activities for this program area are as
follows: A. Infrastructure--Assess current infrastructure needs for a
national, regionalized blood transfusion system, including regional
blood collection and processing facilities, laboratory testing
equipment and supplies. Strengthen regional blood collection facilities
and capacity in major urban areas, preferably near major health care
facilities. Provide standard blood collection and laboratory equipment
and reagents to regional blood collection facilities to collect blood
and test it for transfusion-transmitted infections, and to perform
blood grouping and cross matching.
B. Blood collection--Develop generic and site-specific protocols
for obtaining, handling and storing, transporting, and distributing
blood for use in blood collection facilities. Develop and maintain a
network of blood donor recruiters and blood donor counselors to operate
from each regional center. Develop and maintain a system to identify a
network of low risk and repeat blood donors. Manage blood collection
facilities that have the capacity to obtain, handle and store blood
safely with good recordkeeping. Implement effective quality assurance
procedures for collecting and storing blood.
C. Testing--Develop generic national and site-specific protocols
for testing blood for HIV, hepatitis and syphilis. Manage blood testing
facilities, ensuring good recordkeeping. Implement effective quality
assurance procedures for testing blood.
D. Transfusion and Blood Utilization--Develop and implement
national guidelines for the appropriate use of blood and blood
products, nationally and regionally. Develop blood utilization review
and quality assurance systems for blood usage.
E. Training--Develop and provide training programs and continuing
education programs for health care professionals involved with blood
transfusion services, such as physicians, nurses, physician assistants,
community health aides, counselors, and laboratory technicians in the
fields of blood donor recruitment and blood collection. Develop and
provide training programs and continuing education programs for
physicians and laboratory technicians in basic principles and practice
of blood banking and transfusion medicine. Develop educational programs
for health care providers, nurses and the general public on safe
transfusion practices, including reducing the demand for unnecessary
transfusions and recognizing community norms in practices regarding
blood transfusions.
F. Monitoring and evaluation--Implement a system for reviewing and
adjusting program activities based on monitoring information. Measure
clinical outcomes to assess the impact of the program.
Funding will be provided to initiate new programs or expand
existing programs (e.g., expanding from one region to other regions of
the same country) that include the above components. Technical
assistance in support of the activities listed in this program
announcement will be provided to the Ministries of Health or the
National Transfusion Services by CDC, as well as by the organizations
that successfully compete for funding under a separate CDC cooperative
agreement program announcement focused on the
[[Page 67178]]
provision of technical assistance for blood safety activities in the
targeted countries.
In a cooperative agreement, HHS/CDC staff is substantially involved
in the program activities, above and beyond routine grant monitoring.
HHS will work under the guidance and supervision of the Office of the
Global AIDS Coordinator at the Department of State.
HHS/CDC Activities for this program are as follows:
A. Provide scientific and technical assistance in refining the
operational plan.
B. Provide ongoing technical assistance in addressing problems
encountered in implementing your plan. This may be provided directly by
HHS/CDC staff or through organizations that successfully compete for
funding under a separate HHS/CDC cooperative agreement program
announcement focused on the provision of technical assistance for blood
safety activities with the 14 targeted countries.
C. Assist in assessing program operations and in evaluating overall
effectiveness of your program.
D. Staff in both headquarters (HHS/CDC Atlanta and HHS/CDC in
country) and in the designated countries will assure that other related
U.S. Government activities are well coordinated with National Programs
in each country.
II. Award Information
Type of Award: Cooperative Agreement. HHS/CDC involvement in this
program is listed in the Activities Section above.
Fiscal Year Funds: FY 2004.
Approximate Total Funding: $42 million.
Approximate Number of Awards: 14.
Approximate Average Award: $3 million.
Floor of Award Range: $500,000.
Ceiling of Award Range: $5 million.
Anticipated Award Date: March 25, 2004.
Budget Period Length: 12 months.
Project Period Length: 5 years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required and
certified technically acceptable semi-annual program and financial
reports), and the determination that continued funding is in the best
interest of the U.S. Government.
III. Eligibility Information
III.1. Eligible applicants: Applications may be submitted by
Ministries of Health, National Blood Transfusion Services or their bona
fide agents in the 14 targeted countries: Botswana, C[ocirc]te
d'Ivoire, Ethiopia, Haiti, Guyana, Kenya, Mozambique, Namibia, Nigeria,
Rwanda, South Africa, Tanzania, Uganda, and Zambia.
A Bona Fide Agent is an agency/organization identified by the
Ministry of Health as eligible to submit an application under the
Ministry eligibility in lieu of a Ministry application. If you are
applying as a bona fide agent of a Ministry, you must provide a letter
from the state as documentation of your status. Place this
documentation behind the first page of your application form.
III.2. Cost Sharing or Matching: Matching funds are not required
for this program.
III.3. Other Eligibility Requirements: If you request a funding
amount greater than the ceiling of the award range, your application
will be considered non-responsive and will not be entered into the
review process. You will be notified that your application did not meet
the submission requirements.
Note: Title 2 of the United States Code section 1611 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
IV. Application and Submission Information
IV.1. Address to Request Application Package: To apply for this
funding opportunity use application form PHS 5161. Forms are available
on the United States Government (USG) web site, at the following
Internet address: http://www.cdc.gov/od/pgo/forminfo.htm.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the USG
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Submission: You must submit a signed
original and two copies of your application forms.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the USG. The DUNS number is a nine-digit identification
number, which uniquely identifies business entities. Obtaining a DUNS
number is easy and there is no charge. To obtain a DUNS number, access
http://www.dunandbradstreet.com or call 1-866-705-5711. For more information, see the USG web site at: http://www.cdc.gov/od/pgo/
funding/pubcommt.htm.
If your application form does not have a DUNS number field, please
write your DUNS number at the top of the first page of your
application, and/or include your DUNS number in your application cover
letter.
You must include a project narrative with your application forms.
Your narrative must be submitted in the following format:
[sbull] Maximum number of pages: 30--If your narrative exceeds the
page limit, only the first pages which are within the page limit will
be reviewed.
[sbull] Font size: 12 point unreduced.
[sbull] Paper size: 8.5 by 11 inches.
[sbull] Page margin size: 1''--top, bottom, right, and left.
[sbull] Printed only on one side of page.
[sbull] Held together only by rubber bands or metal clips; not
bound in any other way.
[sbull] Written in English, avoid jargon.
Your narrative should address activities to be conducted over the
entire project period, and must include the following items in the
order listed:
A. Need and Experience (4 Pages Maximum)
Describe the need for services in the country or regions in which
you intend to provide blood transfusion safety services. Provide
evidence that your organization has experience in and is currently
developing or maintaining blood safety programs in one or more of the
following countries: Botswana, C``te d'Ivoire, Ethiopia, Haiti, Guyana,
Kenya, Mozambique, Namibia, Nigeria, Rwanda, South Africa, Tanzania,
Uganda, and Zambia. Address the following:
1. Estimated number of transfusions; age-specific prevalence for
HIV, hepatitis and syphilis; estimated number of transfusion-related
infections from HIV, hepatitis and syphilis-contaminated blood.
2. Estimated number of blood units needed for an adequate blood
supply, the number of additional blood units that must be collected to
meet the supply need, and number of test kits needed annually to test
the entire blood supply for HIV, hepatitis and syphilis.
3. Number of needed regional blood collection and testing centers,
and the population covered by each center.
4. Need for blood safety education and training activities.
5. Need for blood donor selection and recruitment strategies.
[[Page 67179]]
B. Current Blood Bank and Transfusion Service Activities (8 Pages
Maximum)
Describe the blood transfusion system activities for the regions in
which you plan to provide blood transfusion safety services. Address
the following:
1. Infrastructure--Describe the current blood transfusion system
infrastructure, including regional blood collection facilities,
laboratory testing equipment, and supplies. Describe their location and
access to major urban population centers.
2. Blood collection--Describe the current protocols and systems for
collecting, handling and distributing units of blood. Describe the
organization of blood donor recruitment and counseling activities.
Describe the management of blood collection facilities, record-keeping
and quality assurance activities. Describe your activities to promote
blood donor community mobilization in the proposed areas, including
relationships with other organizations that provide services.
3. Testing--Describe the current system of testing blood for HIV,
hepatitis and syphilis. Include a description of the following: (a) the
type and number of laboratory facilities for testing of HIV and other
transfusion transmitted infections; (b) staff qualifications; (c) the
number and types of tests performed by each facility in the past 12
months; and (d) the percent of the blood supply currently tested; (e)
the capability of performing these tests at each facility including
type of equipment used; and (f) current quality assurance procedures.
4. Transfusion and Blood Utilization--Describe current use of
national/regional guidelines for blood transfusion therapy and efforts
or systems for blood utilization review and the reduction of
unnecessary blood transfusions.
5. #Training activities--Describe current training programs for
blood transfusion safety for physicians, laboratory technologists,
donor recruiters and nurses. Include information the types and numbers
of persons trained, training curricula, training facilities, and the
trainers.
6. Monitoring and evaluation--Describe the current system to record
important program indicators such as the monthly number of units of
safe blood made available, the number of persons receiving safe blood
each month, the blood supply deficit, and the number of persons with
serious adverse consequences to transfusions.
C. Goals (4 Pages Maximum)
Address the following:
1. Provide goals, objectives, and timeline for implementation of
the program plan.
2. Provide measures of effectiveness by which you can assess the
success of the program.
3. Provide letters of support from organizations with which you
intend to work. These letters should indicate support for the goals and
objectives of your proposed project and indicate what support they will
provide, e.g., referrals to your program.
D. Rapid Expansion of Blood Transfusion Safety Services (8 Pages
Maximum)
Describe your plans for increasing the quality and extent of safe
blood transfusion services. Describe your plans for increasing the
number of units of safe blood available for transfusion and plans for
reducing unnecessary transfusions. If an applicant plans to sub-
contract out to other organizations, this strategy must be clearly
identified and explained in the application. Address the following
areas:
1. Infrastructure--Describe your plans to assess and expand the
current blood transfusion system infrastructure, including regional
blood collection facilities, laboratory testing and processing
equipment, and supplies.
2. Blood collection--Describe your plans for expanding the current
systems for collecting, handling, and distributing units of blood.
Describe your plans for the expansion of blood donor recruitment and
counseling activities. Describe your plans for the development of blood
collection facilities management, record-keeping and quality assurance
activities. Describe your planned activities to promote blood donor
community mobilization in the proposed areas, including relationships
with other organizations that provide the services.
3. Testing--Describe your plans to expand the current system of
testing blood for HIV, hepatitis, and syphilis. Describe plans to
implement or expand current quality assurance procedures.
4. Transfusion and Blood Utilization--Describe plans to implement
the use of national or regional guidelines for blood transfusion
therapy and efforts or systems for blood utilization review and the
reduction of unnecessary blood transfusions.
5. Training activities--Describe proposed training programs for
blood transfusion safety for physicians, laboratory technologists,
blood donor recruiters, and nurses. Include information about proposed
course titles, types and numbers of persons to be trained, length of
each course, development of training facilities, and trainers.
6. Monitoring and evaluation--Describe the proposed system to use
important program indicators such as the monthly number of units of
safe blood made available, the number of persons receiving safe blood
each month, the blood supply deficit, and the number of persons with
serious adverse consequences to transfusions.
7. Sustainability--Applicants should develop a one-page description
of capacity building activities for each year's work plan. Proposed
activities must include capacity building as defined as activities
promoting host country infrastructure development and strengthening of
management, service delivery, and evaluation systems and clinical/
cultural competency.
In order to accomplish sustainable systems development the
following activities are suggested:
[sbull] Identify key stakeholders and engage potential in-country
partners;
[sbull] Develop or expand a formal (preferably host country)
advisory group to plan for on-going services;
[sbull] Define the components of care with other health or social
service providers;
[sbull] Research funding sources; and
[sbull] Develop an exit plan.
The overall strategy and program must fit into National host
country strategies including continuation of the program funding and
staffing.
E. Management Plan, Staffing, and Infrastructure (6 Pages Maximum)
1. Management plan--Provide an organizational chart and describe
the responsibilities for each of the key staff.
2. Staffing--Describe the number and types of staff needed to
assist with technical guidance and training activities.
3. Infrastructure--Describe the physical facilities in which the
proposed activities will be carried out and the equipment needed.
4. Human Resources, Management and Administration--Describe plans
to provide or obtain all material and human resources necessary for the
development, implementation, management, operation, procurement,
monitoring, and quality assurance of all program activities.
5. Coordination with National Programs--Describe the organization's
strategy to coordinate proposed activities within the context of
national programs.
F. Budget Narrative (No Page Limit)
Guidance for completing your budget can be found on the USG web
site, at the following address: http://www.cdc.gov/od/pgo/funding/budgetguide.htm
.
[[Page 67180]]
Additional information may be included in the application
appendices. The appendices will not be counted toward the narrative
page limit. This additional information includes: Curriculum Vitae,
Resumes, Organizational Charts, Letters of Support, and other pertinent
documents.
IV. 3. Submission Dates and Times:
Application Deadline Date: March 1, 2004.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4:00 p.m. Eastern Time on the deadline
date. If you send your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery of the application by the closing date
and time. If CDC receives your application after closing due to: (1)
carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the application as having
been received by the deadline.
This program announcement is the definitive guide on application
format, content, and deadlines. It supersedes information provided in
the application instructions. If your application does not meet the
deadline above, it will not be eligible for review, and will be
discarded. You will be notified that your application did not meet the
submission requirements.
CDC will not notify you upon receipt of your application. If you
have a question about the receipt of your application, first contact
your courier. If you still have a question, contact the PGO-TIM staff
at: 770-488-2700. Before calling, please wait two to three days after
the application deadline. This will allow time for applications to be
processed and logged.
IV.4. Intergovernmental Review of Applications: Executive Order
12372 does not apply to this program.
IV.5. Funding Restrictions: Funding restrictions, which must be
taken into account while writing your budget are as follows:
[sbull] Funds may be used only for activities associated with
strengthening blood transfusion services. USG funds may be used for
direct costs such as salaries; necessary travel; operating costs,
including supplies, fuel, utilities, etc.; staff training costs,
including registration fees and purchase and rental of training related
equipment; and purchase of HIV testing reagents, test kits, and
laboratory equipment for HIV testing.
[sbull] No funds made available under this solicitation may be used
to provide assistance to any group or organization that does not have a
policy explicitly opposing prostitution and sex trafficking. This
written statement of certification must be signed by authorized
person(s) within the applicant group or organization, including the
individuals submitting the application. No funds made available under
this solicitation may be used to promote or advocated the legalization
or practice of prostitution or sex trafficking. Nothing in the
preceding two sentences shall be construed to preclude the provision to
individuals of palliative care, treatment, or post-exposure
pharmaceutical prophylaxis, and necessary pharmaceuticals and other
commodities, including test kits, condoms, and, when proven effective,
microbicides.
[sbull] No funds appropriated under this solicitation shall be used
to carry out any program of distributing sterile needles or syringes
for the hypodermic use of any illegal drug.
[sbull] Applicants may contract with other organizations under this
program; however, the applicant must perform a substantial portion of
the activities (including program management and operations, and
delivery of services for which funds are requested).
[sbull] The costs that are generally allowable in grants to
domestic organizations are allowable to foreign institutions and
international organizations, with the following exception: With the
exception of American University, Beirut and the World Health
Organization, indirect costs will not be paid (either directly or
through a sub-award) to organizations located outside the territorial
limits of the United States or to international organizations
regardless of their location.
[sbull] All requests for funds contained in the budget shall be
stated in U.S. dollars. Once an award is made, the U.S. Government will
not compensate foreign grantees for currency exchange fluctuations
through the issuance of supplemental awards.
[sbull] A fiscal Recipient Capability assessment may be required,
prior to or post award, in order to review the applicant's business
management and fiscal capabilities regarding the handling of U.S.
Federal funds.
[sbull] You must obtain an annual audit of these U.S. Government
funds (program-specific audit) by a U.S.--based audit firm with
international branches and current licensure/authority in-country, and
in accordance with International Accounting Standards or equivalent
standard(s) approved in writing by the U.S. Government.
IV.6. Other Submission Requirements: Submit your application by
mail or express delivery service to: Technical Information Management--
PA04077, CDC Procurement and Grants Office, 2920 Brandywine
Road, Atlanta, GA 30341, USA.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria: You are required to provide measures of
effectiveness that will demonstrate the accomplishment of the various
identified objectives of the cooperative agreement. Measures of
effectiveness must relate to the performance goals stated in the
``Purpose'' section of this announcement. Measures must be objective
and quantitative, and must measure the intended outcome. These measures
of effectiveness must be submitted with the application and will be an
element of evaluation. These should be included in your project
narrative under ``Goals.''
Your application will be evaluated against the following criteria:
1. Current capability: 55 Points
(a) Infrastructure/Experience--Does the applicant have the
resources as well as demonstrated experience necessary to develop blood
center infrastructure, including buildings, equipment, and supplies?
(b) Blood collection--Does the applicant have the resources to
develop blood collection facilities and blood donor recruitment
networks?
(c) Testing--Does the applicant have the resources to develop blood
transfusion testing laboratories, including standard operating
procedures protocols?
(d) Transfusion and Blood Utilization--Does the applicant have the
resources to develop blood transfusion practice guidelines and a blood
utilization review program?
(e) Training--Does the applicant have the resources to develop a
comprehensive training program in the basic principles and practices of
blood banking and transfusion medicine?
(f) Monitoring and evaluation--Is there a monitoring and evaluation
plan in place? Does the plan measure important indicators?
(g) Management and Administration--Does the applicant have the
resources to
[[Page 67181]]
manage and administer a national blood transfusion system?
2. Feasibility of Plan: 35 Points
(a) Infrastructure--Is the plan to develop blood center
infrastructure sound and reasonable?
(b) Blood collection--Is the plan to develop blood collection
facilities, including the development of blood donor recruitment
networks, reasonable?
(c) Testing--Is the plan to develop blood transfusion testing
laboratories, including standard operating procedures and protocols,
reasonable?
(d) Transfusion and Blood Utilization--Does the applicant's plan to
develop blood transfusion practice guidelines and a blood utilization
review program seem reasonable?
(e) Training--Does the applicant have the resources and a
reasonable plan to develop a comprehensive training program in the
basic principles and practices of blood banking and transfusion
medicine?
(f) Monitoring and evaluation--Is the monitoring and evaluation
plan feasible? Does the plan measure important indicators?
(g) Sustainability--Is the plan for sustainability reasonable and
feasible?
3. Measures of Effectiveness: 10 Total
Do the measures of effectiveness address the number of blood units
tested safe for transfusion-transmitted diseases and the number of
persons receiving safe transfusions?
V.2. Review and Selection Process: Applications will be reviewed
for completeness by the Procurement and Grants Office (PGO) staff, and
for responsiveness by the National Center for HIV, STD, and TB
Prevention. Incomplete applications and applications that are non-
responsive to the eligibility criteria will not advance through the
review process. Applicants will be notified that their application did
not meet submission requirements.
An interagency objective review panel will evaluate complete and
responsive applications according to the criteria listed in the ``V.1.
Criteria'' section above.
In addition, the following factors may affect the funding decision:
[sbull] Geographic distribution
[sbull] Percentage of staff who are citizens of the country in
which services will be provided.
V.3. Anticipated Announcement and Award Dates:
Award Date: March 25,2004.
VI. Award Administration Information
VI.1. Award Notices: Successful applicants will receive a Notice of
Grant Award (NGA) from the USG Procurement and Grants Office. The NGA
shall be the only binding, authorizing document between the recipient
and USG. The NGA will be signed by an authorized Grants Management
Officer, and mailed to the recipient fiscal officer identified in the
application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements: 45 CFR part
74 and part 92.
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
[sbull] AR-4 HIV/AIDS Confidentiality Provisions.
[sbull] AR-5 HIV Program Review Panel Requirements.
[sbull] AR-6 Patient Care.
[sbull] AR-9 Paperwork Reduction Act Requirements.
[sbull] AR-10 Smoke-Free Workplace Requirements.
[sbull] AR-11 Healthy People 2010.
[sbull] AR-12 Lobbying Restrictions.
[sbull] AR-14 Accounting System Requirements.
[sbull] AR-16 Security Clearance Requirement.
[sbull] AR-23 States and Faith-Based Organizations.
[sbull] AR-24 Health Insurance Portability and Accountability Act
Requirements.
[sbull] AR-25 Release and Sharing of Data.
Additional information on these requirements can be found on the
CDC web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
Reporting Requirements: You must provide CDC with a hard copy
original, plus two copies of the following reports:
1. Interim progress report, no less than 90 days before the end of
the budget period The progress report will serve as your non-competing
continuation application, and must contain the following elements:
(a) Current Budget Period Activities Objectives.
(b) Current Budget Period Financial Progress.
(c) New Budget Period Program Proposed Activity Objectives.
(d) Detailed Line-Item Budget and Justification.
(e) Additional Requested Information.
2. Semi-annual progress report, due 7 months after the beginning of
each budget period. This report should contain the following elements:
(a) Progress on achieving objectives
(b) Modification or new activities
3. Financial status report, no more than 90 days after the end of
the budget period.
4. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be sent to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
VII. Agency Contacts
For general questions about this announcement, contact: Technical
Information Management Section, CDC Procurement and Grants Office, 2920
Brandywine Road, Atlanta, GA 30341, Telephone: (770) 488-2700.
For program technical assistance, contact: Kenneth Clark, M.D.,
MPH, Project Officer, National Center for HIV, STD, and TN Prevention,
Centers for Disease Control and Prevention, 1600 Clifton Rd, NE, MS
E04, Atlanta, GA 30333, Telephone: (404) 639-8057, E-mail: kjc4@cdc.gov.
For budget assistance, contact: Shirley Wynn, Contract Specialist,
CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: (770) 488-1515, E-mail: zbx6@cdc.gov.
Dated: November 25, 2003.
Edward Schultz,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 03-29891 Filed 11-28-03; 8:45 am]
BILLING CODE 4163-18-P